TGTX entered an agreement with Neuraxpharm Group for the ex-US commercialization of BRIUMVI (ublituximab), a treatment for relapsing multiple sclerosis, under which TG Therapeutics will receive an upfront payment of $140 million plus an additional $12.5 million upon BRIUMVI's first EU launch along with up to $492.5 million in potential milestone payments.

TG Therapeutics Inc. TGTX 暴跌。$TG治疗(TGTX)$